Pimitespib

Pimitespib (trade name Jeselhy) is a drug for the treatment of gastrointestinal stromal tumors.[1] It was discovered and developed by Taiho Pharmaceutical Co.[2] The mechanism of action of pimitespib involves inhibition of heat shock protein 90 (Hsp90).[3]

Pimitespib
Clinical data
Trade namesJeselhy
Other namesTAS 116
Legal status
Legal status
  • Rx in Japan
Identifiers
CAS Number
UNII
KEGG
Chemical and physical data
FormulaC25H26N8O
Molar mass454.538 g·mol−1
3D model (JSmol)
  • O=C(N)C1=CC=C(C(=C1)CC)N2N=C(C=3C2=NC=CC3N4C=NC(=C4)C=5C=NN(C5)C)C(C)C

In June 2022, it received approval in Japan for gastrointestinal stromal tumors that have progressed after chemotherapy.[4]

References
  1. "Pimitespib - Taiho Pharmaceutical". Adis Insight.
  2. "Taiho Pharmaceutical Obtains Approval to Manufacture and Market HSP90 inhibitor Jeselhy® Tablets 40 mg (Pimitespib) for Gastrointestinal Stromal Tumor (GIST)" (Press release). Taiho Pharmaceutical. June 20, 2022.
  3. Kurokawa Y, Honma Y, Sawaki A, Naito Y, Iwagami S, Komatsu Y, et al. (June 2022). "Pimitespib in patients with advanced gastrointestinal stromal tumor (CHAPTER-GIST-301): a randomized, double-blind, placebo-controlled phase III trial". Annals of Oncology. doi:10.1016/j.annonc.2022.05.518. PMID 35688358. S2CID 249532381.
  4. Hoy SM (August 2022). "Pimitespib: First Approval". Drugs. doi:10.1007/s40265-022-01764-6. PMID 35986838. S2CID 251672805.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.